These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 33934231

  • 1. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.
    Guy A, Bidet A, Ling C, Caumont C, Boureau L, Viallard JF, Parrens M.
    Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231
    [Abstract] [Full Text] [Related]

  • 2. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.
    Pizzi M, Gergis U, Chaviano F, Orazi A.
    Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B, Diral E, Donsante S, Di Marzo N, Mottadelli F, Cardinale L, Dander E, Isimbaldi G, Pioltelli P, Biondi A, Riminucci M, D'Amico G, Elli EM, Pievani A, Serafini M.
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 7. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
    Barosi G.
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
    [Abstract] [Full Text] [Related]

  • 8. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.
    Song MK, Park BB, Uhm JE.
    Int J Mol Sci; 2018 Mar 18; 19(3):. PubMed ID: 29562644
    [Abstract] [Full Text] [Related]

  • 9. Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis.
    Collinson RJ, Wilson L, Boey D, Ng ZY, Mirzai B, Chuah HS, Howman R, Grove CS, Malherbe JAJ, Leahy MF, Linden MD, Fuller KA, Erber WN, Guo BB.
    Platelets; 2024 Dec 18; 35(1):2304173. PubMed ID: 38303515
    [Abstract] [Full Text] [Related]

  • 10. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J, Kvasnicka HM.
    Pathobiology; 2007 Dec 18; 74(2):89-96. PubMed ID: 17587880
    [Abstract] [Full Text] [Related]

  • 11. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
    Sangiorgio VFI, Nam A, Chen Z, Orazi A, Tam W.
    Leuk Res; 2021 Jan 18; 100():106495. PubMed ID: 33360878
    [Abstract] [Full Text] [Related]

  • 12. Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives.
    Barosi G, Rosti V, Gale RP.
    Leukemia; 2023 Apr 18; 37(4):725-727. PubMed ID: 36871061
    [Abstract] [Full Text] [Related]

  • 13. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar 18; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 14. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
    Tovar-Bobadilla JL, Ortiz-Hidalgo C.
    Gac Med Mex; 2016 Mar 18; 152(3):407-18. PubMed ID: 27335198
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S.
    Leuk Res; 2017 Aug 18; 59():110-116. PubMed ID: 28601551
    [Abstract] [Full Text] [Related]

  • 18. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.
    Sangle N, Cook J, Perkins S, Teman CJ, Bahler D, Hickman K, Wilson A, Prchal J, Salama ME.
    Appl Immunohistochem Mol Morphol; 2014 Oct 18; 22(9):663-8. PubMed ID: 24897074
    [Abstract] [Full Text] [Related]

  • 19. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation.
    Khanlari M, Wang X, Loghavi S, Wang SA, Li S, Thakral B, Bueso-Ramos CE, Yin CC, Kanagal-Shamanna R, Khoury JD, Patel KP, Popat UR, Medeiros LJ, Konoplev S.
    Ann Diagn Pathol; 2022 Feb 18; 56():151860. PubMed ID: 34823075
    [Abstract] [Full Text] [Related]

  • 20. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
    Cerquozzi S, Tefferi A.
    Blood Cancer J; 2015 Nov 13; 5(11):e366. PubMed ID: 26565403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.